Premium
Evaluation of Ki‐67 Monoclonal Antibody as Prognostic Indicator for Prostatic Carcinoma
Author(s) -
McLOUGHLIN J.,
FOSTER C. S.,
PRICE P.,
WILLIAMS GORDON,
ABEL P. D.
Publication year - 1993
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1993.tb06466.x
Subject(s) - medicine , monoclonal antibody , ki 67 , immunostaining , prostate cancer , carcinoma , prostate , pathology , hyperplasia , adenocarcinoma , prostate specific antigen , cancer , antigen , antibody , oncology , immunohistochemistry , immunology
Summary— Prostate tissue containing either primary adenocarcinoma (45 patients) or benign hyperplasia (15 patients) was immunostained with the monoclonal antibody Ki‐67, which recognises a human nuclear antigen expressed by human cycling cells. The percentage of cells staining positive was considered a measure of proliferation. This derived Ki‐67 index was higher for carcinomas than for hyperplastic glands. Within the group of carcinomas, KI‐67 indices in patients with metastatic disease were significantly higher than in those without and there was a trend towards increasing Ki‐67 indices with increasing Gleason grade. When patients with prostate cancer were prospectively followed up, the Ki‐67 index did not predict either disease progression or hormone responsiveness. Ki‐67 immunostaining may define a group of patients with prostate cancer of poor prognosis.